Default company panoramic image
16db370f 53f1 4749 9d79 910bbad176f6

CloSys Corporation

CloSys is testing in a U.S. pivotal trial a vascular closure system designed to meet all the requirements of a $1 billion per year market.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location United States
  • Currency USD
  • Founded March 2005
  • Employees 2
  • Website

Company Summary

CloSys has developed a product that is used to seal a large arterial puncture wound created to allow access to heart and peripheral arteries for interventional procedures such as angioplasty or stent placement. The product offers economic advnatages to the hospital in terms of more efficient use of high revenue producing laboratories and significantly improves patient comfort. Combined coronary and peripheral interventional markets: $1Billion


  • Default avatar
    Gervaise Lee Wilhelm

    Ms Wilhelm is a veteran of 5 previous start up companies functioning founder, officer and director. Life Sciences have been the focus of each company. Exits have included both public offerings and acquistions by strategic organizations. Her credentials include certificaton by the American Soc of Cl Patholgoy, BS degree in Medical Technology and an MBA. She is a certified Physician Assistant in cardiopulmonary medicine.

  • Default avatar
    Karol George Nowakowski

    Mr. Nowakowski is the founder and inventor of the technology and sole inventor on the patents that protect the CloSys prducts and are assigned to the company. His experience includes directly related R&D at Angion and BBraun . He holds an MBA from the Carlson School at the University of MN and has particular expertise in patent strategy

  • Default avatar
    Mary Lach

    Ms. Lach has 25 years of experience working with large accounting firms (CPA) and with small companies. She has been a part of the CloSys organization since inception

  • Default avatar
    Kelly Elliott
    Clinical trial study diretor

    Ms. Elliott is CEO of Eminence a Contract Research Organization (CRO) and Biostatistics and data management firm. She is a BSN MS registered nurse with considerable experience in the field of interventional cardiology

  • Default avatar
    Mary Beth Henderson
    Regulatory Affairs consultant

    Dr. Henderson has 25 years of experience working with small and large companies as they interface with the FDA. Her experience includes quality systems development and management, global regulatory strategy development and execution and product and process development.

  • Default avatar
    George Adams MD
    Principal Investigator Clinical trial

    Dr. Adams is chief of interventional cardiology at Rex Heathcare in Raleigh, NC. He is actively involved in the emerging speciality of peripheral vascular interventional medicine. He is conducting clinical trials on innovative products designed to treat vascular disease using a catheter approach rather than with open surgical methods..

  • Default avatar
    Bruce Johnson
    Chairman of the Board

    Mr. Johnson served as inside counsel in Europe and in the US for Medtronic for more than 20 years. He is currently of counsel at Fredrikson and Byron a private law firm in Minneapolis where he serves in advisory capacity and board member to early stage medical device companies.

  • Default avatar
    Kendall Price MD
    Chief Hematology Consultant

    Dr. Price is a practicing hematopathologist at HealthEast Clinical Pathology Laboratories in St. Paul, MN. He advises the company on product development matters. He is a graduate of the University of Chicago School of Medicine and hematopathologies residencies at Stanford University in Palo Alto, CA.


  • Default avatar
    Douglas Ramler - securities counsel Charles Sara Patent counsel
    Default avatar
    Mary Lach CPA; Wilkerson and Associates auditors

Previous Investors

  • Default avatar
    Norris Institute Minneapolis, MN
    Default avatar
    Threshold Ventures Scottsdale, AZ
    Default avatar
    High networth individuals Business Angels